Drug Allergy Clinical Trial
— MDHOfficial title:
Multiple Drug Hypersensitivity Syndrome in a Large Database
Verified date | November 2019 |
Source | University Hospital, Montpellier |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background: Multiple drug hypersensitivity syndrome (MDH) is defined as confirmed drug
hypersensitivity reactions (DHRs) to at least 2 chemically and pharmacologically unrelated
drugs. Reports of MDH are scarce and poorly specified and studies which diagnose MDH on the
basis of positive allergy tests are lacking.
Objective: To evaluate retrospectively the frequency and characteristics of MDH patients in a
large database.
Methods: All the patients who consulted and were tested in our Allergy Unit between September
1996 and February 2018, with confirmed MDH will be included. Clinical history and allergy
work-up results will be extracted from our Drug Allergy and Hypersensitivity Database (DAHD).
The frequency of MDH will be calculated, MDH patients will be described, the most frequent
associations of DHRs will be identified and analysed.
Status | Completed |
Enrollment | 50 |
Est. completion date | July 31, 2019 |
Est. primary completion date | June 30, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion criteria: - Patients who consulted at our allergy clinic (University Hospital of Montpellier, France) - Between September 1996 and February 2018 with a clinical history suggestive of DHR - Who completed a tailored drug allergy work-up, (including a drug allergy questionnaire, skin tests (STs) and drug provocation tests (DPTs)) and were diagnosed with MDH. Exclusion criteria: - the DHR was due to a single component contained in 2 different drug formulations - in composed drugs; - there was possible cross-reactivity between the responsible drugs; (iv) the patient had positive but non standardized nor validated (i.e. possibly irritant) - these STs were followed by a negative DPT; - DPTs with placebo were positive; (vii) doubtful tests were repeated and eventually considered negative; - a single DHR was associated with one or more non-drug related contact allergies; - DPTs elicited subjective manifestations (i.e., isolated pruritus, headache, isolated abdominal pain); - non-specific histamine release was suspected (e.g., chronic spontaneous - desensitization, rather than a diagnostic work-up was preferred in order to meet the urgent therapeutic needs of individual patients (HIV infected patients, cardiac patients). |
Country | Name | City | State |
---|---|---|---|
France | University hospital of Montpellier | Montpellier |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Montpellier |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To measure retrospectively the frequency of MDH patients in our database. | The frequency of MDH patients (percentage) in the allergic group of patients will be calculated as the number of MDH patients divided by the number of monoallergic patients (frequency of MDH patients in allergic population) | 1 day | |
Primary | To measure retrospectively the frequency of MDH patients in our database | The frequency of MDH in common population will be calculated by will be calculated as the number of MDH patients divided by the number of patients that underwent diagnostic drug allergy testing within the same time frame (frequency of MDH patients in the whole population | 1 day | |
Secondary | To describe the MDH population, identify the most frequent associations of DHR | In this MDH patients population we will : Count the number of female and male patient according to their sex (No unit) | 1 day | |
Secondary | To describe the MDH population, identify the most frequent associations of DHR | In this MDH patients population we will : Most frequent associations of DHR (No unit) | 1 day | |
Secondary | To describe the MDH population, identify the most frequent associations of DHR | In this MDH patients population we will : Count and classify the different form of DHR according to their severity with the Ring and Messsmer and Regiscar study group scoring. (No unit) (ex: number of patient with grade III anaphylaxis or number of patient with DRESS syndrome ) | 1 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT06414694 -
Inpatient Penicillin Delabeling for Low-Risk Patients
|
Phase 4 | |
Completed |
NCT05706246 -
Perioperative Hypersensitivity in Children
|
N/A | |
Recruiting |
NCT04920721 -
Retrospective Study of Immediate Hypersensitivity (IHS) Reactions to Platinum Salts in the University Hospital of Nancy
|
||
Completed |
NCT02118987 -
Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization
|
Phase 1 | |
Enrolling by invitation |
NCT03164044 -
Improved Basophil Activation Test (BAT) in the Diagnostics of Drug Allergy
|
||
Completed |
NCT02094638 -
Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study
|
N/A | |
Not yet recruiting |
NCT06399601 -
A Training Program of Drug Allergy for Healthcare Professionals
|
N/A | |
Not yet recruiting |
NCT06406114 -
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
|
Phase 2 | |
Recruiting |
NCT05820802 -
High Dimensional Analysis of Immune Cells in Pediatric Patients
|